Nuvectis Pharma (NVCT) EPS (Basic) (2021 - 2026)
Nuvectis Pharma (NVCT) posted EPS (Basic) of -$0.26 for Q1 2026, up 22.94% sequentially from -$0.34 in Q4 2025, and up 3.38% YoY from -$0.25 in Q1 2025.
Powered by 
Analysis
Nuvectis Pharma (NVCT) EPS (Basic) (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported EPS (Basic) for 6 years, with the latest figure at -$0.26 in Q1 2026.
- Quarterly EPS (Basic) rose 3.38% year-over-year to -$0.26 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.26 (down 24.97% YoY) and the FY2025 annual result came in at -$1.32, down 19.21% from the prior year.
- EPS (Basic) advanced to -$0.26 in Q1 2026 per NVCT's latest filing, from -$0.34 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$0.24 in Q3 2024 and troughed at -$0.53 in Q4 2022.
- A 5-year average of -$0.34 and a median of -$0.32 in 2022 frame the typical range for EPS (Basic).
- The sharpest annual moves came in 2022 and 2025: EPS (Basic) surged 80.36% in 2022, then tumbled 80.63% in 2025.
- Over 5 years, EPS (Basic) stood at -$0.53 in 2022, then rose by 19.53% to -$0.43 in 2023, then rose by 14.23% to -$0.37 in 2024, then gained by 8.16% to -$0.34 in 2025, then increased by 22.94% to -$0.26 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$0.26, -$0.34, and -$0.44 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | Nuvectis Pharma | 573.99 Mn | 573.99 Mn | - | -0.30 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.30 |
| Mar 31, 2026 | -0.26 |
| Dec 31, 2025 | -0.34 |
| Sep 30, 2025 | -0.44 |
| Jun 30, 2025 | -0.30 |
| Mar 31, 2025 | -0.27 |
| Dec 31, 2024 | -0.37 |
| Sep 30, 2024 | -0.24 |
| Jun 30, 2024 | -0.26 |
| Mar 31, 2024 | -0.25 |
| Dec 31, 2023 | -0.43 |
| Sep 30, 2023 | -0.37 |
| Jun 30, 2023 | -0.38 |
| Mar 31, 2023 | -0.27 |
| Dec 31, 2022 | -0.53 |
| Sep 30, 2022 | -0.42 |
| Jun 30, 2022 | -0.28 |
| Mar 31, 2022 | -0.32 |
| Dec 31, 2021 | -0.53 |
| Sep 30, 2021 | -1.04 |